CHMP recommends licence extension for etravirine (Intelence)

The CHMP have recommended a licence extension to cover the use of etravirine, in combination with a boosted protease inhibitor and other antiretroviral medicinal products for HIV 1 infection, for patients from 2 years of age (currently licenced for patients 6 years old and over).


European Medicines Agency